S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The Day of Financial Reckoning Is Near (Ad)
NASDAQ:HCAT

Health Catalyst - HCAT Competitors

$13.54
+0.26 (+1.96%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.97
$13.61
50-Day Range
$11.35
$18.27
52-Week Range
$10.95
$57.19
Volume
839,699 shs
Average Volume
903,638 shs
Market Capitalization
$740.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.69

HCAT vs. IPSC, PHAR, AVIR, COLL, CARA, ANAB, EHAB, IMAB, BVS, and RAPT

Should you be buying Health Catalyst stock or one of its competitors? The main competitors of Health Catalyst include Century Therapeutics (IPSC), Pharming Group (PHAR), Atea Pharmaceuticals (AVIR), Collegium Pharmaceutical (COLL), Cara Therapeutics (CARA), AnaptysBio (ANAB), Enhabit (EHAB), I-Mab (IMAB), Bioventus (BVS), and RAPT Therapeutics (RAPT). These companies are all part of the "medical" sector.

Health Catalyst vs.

Century Therapeutics (NASDAQ:IPSC) and Health Catalyst (NASDAQ:HCAT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations.

In the previous week, Health Catalyst had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 12 mentions for Health Catalyst and 11 mentions for Century Therapeutics. Health Catalyst's average media sentiment score of 0.61 beat Century Therapeutics' score of 0.55 indicating that Health Catalyst is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Century Therapeutics
0 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Health Catalyst
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

57.5% of Century Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Health Catalyst shares are held by institutional investors. 10.3% of Century Therapeutics shares are held by company insiders. Comparatively, 1.5% of Health Catalyst shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Century Therapeutics presently has a consensus price target of $27.00, indicating a potential upside of 110.61%. Health Catalyst has a consensus price target of $26.69, indicating a potential upside of 97.14%. Given Century Therapeutics' higher possible upside, analysts clearly believe Century Therapeutics is more favorable than Health Catalyst.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Century Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Health Catalyst
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.92

Century Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Health Catalyst has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Century Therapeutics has higher earnings, but lower revenue than Health Catalyst. Century Therapeutics is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Century TherapeuticsN/AN/A-$95.82 million-$1.92-6.68
Health Catalyst$241.93 million3.06-$153.21 million-$2.92-4.64

Century Therapeutics has a net margin of 0.00% compared to Health Catalyst's net margin of -54.64%. Health Catalyst's return on equity of -18.31% beat Century Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Century Therapeutics N/A -31.39% -24.66%
Health Catalyst -54.64% -18.31% -11.16%

Health Catalyst received 114 more outperform votes than Century Therapeutics when rated by MarketBeat users. Likewise, 71.10% of users gave Health Catalyst an outperform vote while only 45.00% of users gave Century Therapeutics an outperform vote.

CompanyUnderperformOutperform
Century TherapeuticsOutperform Votes
9
45.00%
Underperform Votes
11
55.00%
Health CatalystOutperform Votes
123
71.10%
Underperform Votes
50
28.90%

Summary

Health Catalyst beats Century Therapeutics on 13 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCAT vs. The Competition

MetricHealth CatalystComputer & Data IndustryMedical SectorNASDAQ Exchange
Market Cap$740.95M$47.18B$4.39B$6.38B
Dividend YieldN/A0.72%7.34%3.17%
P/E Ratio-4.6477.52123.3818.51
Price / Sales3.062,163.862,940.91128.88
Price / CashN/A36.4622.6729.84
Price / Book1.353.966.436.21
Net Income-$153.21M$2.29B$166.90M$239.70M
7 Day Performance15.83%4.53%4.68%4.54%
1 Month Performance-15.90%11.07%10.78%12.20%
1 Year Performance-74.15%-41.32%-26.68%-20.33%

Health Catalyst Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IPSC
Century Therapeutics
1.8272 of 5 stars
$11.58
-11.6%
$27.00
+133.2%
-59.8%$681.48MN/A-3.50170Short Interest ↓
PHAR
Pharming Group
0 of 5 stars
$10.38
+1.3%
N/A+4.1%$677.61M$198.87M0.00262Gap Up
AVIR
Atea Pharmaceuticals
1.8334 of 5 stars
$8.27
-2.5%
$8.00
-3.3%
-69.0%$688.54M$351.37M16.2259Analyst Report
Short Interest ↓
Gap Up
COLL
Collegium Pharmaceutical
2.0838 of 5 stars
$19.79
+2.3%
$33.25
+68.0%
+5.9%$675.35M$276.87M-18.85152Analyst Downgrade
CARA
Cara Therapeutics
2.0588 of 5 stars
$12.56
+6.4%
$26.80
+113.4%
-15.2%$673.10M$23.03M-7.0684Positive News
ANAB
AnaptysBio
1.6348 of 5 stars
$23.87
+3.1%
$39.50
+65.5%
+8.6%$672.80M$63.17M-8.68102Short Interest ↑
EHAB
Enhabit
1.4007 of 5 stars
$13.41
+2.3%
$16.00
+19.3%
N/A$669.16M$1.11B0.0010,593
IMAB
I-Mab
2.3732 of 5 stars
$8.09
+1.5%
$68.25
+743.6%
-88.6%$668.61M$13.81M0.00228Short Interest ↓
BVS
Bioventus
1.852 of 5 stars
$8.66
+3.2%
$22.50
+159.8%
-41.3%$668.09M$430.90M-26.241,200Earnings Report
Gap Up
RAPT
RAPT Therapeutics
2.038 of 5 stars
$23.64
+4.9%
$50.50
+113.6%
-9.0%$700.86M$3.81M-9.2381News Coverage
Gap Up
This page (NASDAQ:HCAT) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.